Results · Apr-Jun 2026
Zydus Lifesciences Q1 FY27 results
Sales grew 22% to ₹8,017 crore from ₹6,574 crore in Apr-Jun 2025.
Operating profit fell 8% to ₹1,929 crore, an operating margin of 24.1% (down 7.7 points from a year ago).
Net profit fell 35% to ₹990 crore from ₹1,521 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +6%, net profit −26%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 8,017 | 6,574 | +22% |
| Operating profit (EBITDA) | 1,929 | 2,089 | −8% |
| Operating margin | 24.1% | 31.8% | −7.7 pts |
| Net profit | 990.2 | 1,521 | −35% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.